Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
GSK plc announces major three-part transaction with Novartis to drive sustainable sales growth, improve long-term earnings and deliver increasing returns to shareholders
GSK announces a major conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses
GSK and Theravance announce phase III study of fluticasone furoate/vilanterol in COPD commenced to support potential future filing in Japan
GSK and THRX today announced the start of a Phase III efficacy and study of a combination treatment of the inhaled corticosteroid (ICS).
GSK announces approval in Canada for Incruse Ellipta (umeclidinium) as a treatment for COPD
GSK announced that Incruse™Ellipta™ has received market authorisation in Canada for bronchodilator airflow obstruction in patients with COPD
GSK and Genmab receive FDA approval for Arzerra
GSK & GEN announced today that the FDA has approved a sBLA for Arzerra® (ofatumumab) for CLL
GSK statement on media reports
There has been recent publicity on cases of alleged misconduct by GSK employees in a number of countries.
GSK receives US approval for once-weekly type 2 diabetes treatment, Tanzeum™ (albiglutide)
GSK today announced that the FDA has approved TanzeumTM (albiglutide) for injection, as a once-weekly treatment for type 2 diabetes.
GSK statement on BBC Panorama programme
GSK issued the following statement in response to claims by BBC Panorama related to GSK in Poland, to be broadcast on Monday April 14 2014
Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer
GSK announced its decision to stop the Phase III trial of MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer patients.
ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool
ViiV announced new collaborations to increase access to its HIV medicine, dolutegravir ( Tivicay®), just after approval by EMA & FDA.
Results from phase III patient preference study of GSK’s Votrient® (pazopanib) vs. Sutent® (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology
Data from the first patient preference study in advanced renal cell carcinoma have been published in the Journal of Clinical Oncology.
Regulatory update: Votrient® (pazopanib) as maintenance therapy for advanced ovarian cancer in the EU
GSK today announced that it has withdrawn application to EMA for a variation to the Marketing Authorisation for Votrient® (pazopanib).
GSK announces new strategic investments in Africa to increase access to medicines, build capacity and deliver sustainable growth
GSK today announced a series of investments in sub-Saharan Africa designed to address pressing needs and contribute to long-term growth.
GSK presents data from Phase III STABILITY study of darapladib in patients with chronic coronary heart disease
GSK presented data from the pivotal Phase III STABILITY study of darapladib at the American College of Cardiology 63rd Annual Session
GSK acquires full ownership of its Indonesian Consumer Healthcare business
GSK has acquired full ownership of its Indonesian Consumer Healthcare business
Where do you start when developing a new medicine?
Initiative between GSK, EMBL-EBI and Sanger Institute is using ‘big data’ & genome sequencing improving chances for discovering new drugs.
Regulatory update: combined use of Mekinist™ (trametinib) and Tafinlar® (dabrafenib) in Europe
GSK today announced that it has withdrawn its MAA to EMA for the use of Mekinist (trametinib) in combination with Tafinlar (dabrafenib).
GSK receives European authorisation for once-weekly type 2 diabetes treatment, Eperzan® (albiglutide)
GSK announced that the EC has granted marketing authorisation for its once-weekly diabetes treatment, Eperzan® (albiglutide).
GSK publishes historical quarterly restated financial information
GSK will adopt a revised presentation for the analysis of its Pharmaceuticals and Vaccines turnover by segment, product and therapeutic area
Investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoints in MAGRIT, a phase III non-small cell lung cancer clinical trial
GSK announced that the MAGRITi phase III trial of MAGE-A3 cancer immunotherapeuticii in NSCLC patients did not meet its primary endpoint.
GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS® and ADVAIR® DISKUS® in patients with COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from three phase III studies.